1
Clinical Trials associated with Allogeneic EBV-specific anti-CD19 CAR-T cell therapy(Memorial Sloan-Kettering Cancer Center) / Active, not recruitingPhase 1IIT A Phase I Trial Using In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
The purpose of this study is to test the safety of giving the patient special cells from a donor called "Modified T-cells". The goal is to assess the toxicities of T-cells for patients with relapsed B cell leukemia or lymphoma after a blood SCT organ SCT or for patients who are at high risk for relapse of their B cell leukemia or lymphoma.
100 Clinical Results associated with Allogeneic EBV-specific anti-CD19 CAR-T cell therapy(Memorial Sloan-Kettering Cancer Center)
100 Translational Medicine associated with Allogeneic EBV-specific anti-CD19 CAR-T cell therapy(Memorial Sloan-Kettering Cancer Center)
100 Patents (Medical) associated with Allogeneic EBV-specific anti-CD19 CAR-T cell therapy(Memorial Sloan-Kettering Cancer Center)
100 Deals associated with Allogeneic EBV-specific anti-CD19 CAR-T cell therapy(Memorial Sloan-Kettering Cancer Center)